0001088020-11-000023.txt : 20110303
0001088020-11-000023.hdr.sgml : 20110303
20110303165606
ACCESSION NUMBER: 0001088020-11-000023
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20110301
FILED AS OF DATE: 20110303
DATE AS OF CHANGE: 20110303
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PALATIN TECHNOLOGIES INC
CENTRAL INDEX KEY: 0000911216
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 954078884
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 4C CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: 609-495-2200
MAIL ADDRESS:
STREET 1: 4C CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: INTERFILM INC
DATE OF NAME CHANGE: 19930825
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: WILLS STEPHEN T
CENTRAL INDEX KEY: 0001103883
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-15543
FILM NUMBER: 11660894
MAIL ADDRESS:
STREET 1: PALATIN TECHNOLOGIES, INC.
STREET 2: 4C CEDAR BROOK DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0303
4
2011-03-01
0
0000911216
PALATIN TECHNOLOGIES INC
PTN
0001103883
WILLS STEPHEN T
PALATIN TECHNOLOGIES, INC.
4C CEDAR BROOK DRIVE
CRANBURY
NJ
08512
0
1
0
0
Exec VP - Operations & CFO
common stock
2011-03-01
4
P
0
50000
A
98024
D
Series A common stock purchase warrant
1
2011-03-01
4
P
0
4348
A
2011-03-01
2016-03-01
common stock
4348
4348
D
Series B common stock purchase warrant
1
2011-03-01
4
P
0
45652
A
2012-03-02
2017-03-02
common stock
45652
45652
D
Included in the purchase of 50,000 Units at a price of $1.00 per Unit. Each Unit consisted of one share of common stock; a Series A Warrant exercisable immediately for 2/23 of a share of common stock at an exercise price of $1.00 per share, with an expiration date of March 1, 2016; and a Series B Warrant exercisable starting March 2, 2012 for 21/23 of a share of common stock at an exercise price of $1.00 per share, with an expiration date of March 2, 2017. Exercise of the Series B warrant is subject to stockholder approval of an increase in the issuer's authorized capital.
Stephen T. Wills
2011-03-03